Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Barchart

Weight loss injection to be made available in UK within weeks

Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity

The Guardian - UK

$100 million gift from Lilly Endowment aims to shore up HBCU endowments

The United Negro College Fund announced a donation of $100 million from the Lilly Endowment, the single largest unrestricted gift to the organization since its founding 80 years ago

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Iron Condor Alert: LLY Stock Could Net 40% In 4 Weeks

Eli Lilly (LLY) is showing elevated implied volatility with an IV Percentile of 98%, and that could mean it’s a good time for an iron condor trade.

Barchart

Eli Lilly starts website to connect patients with new obesity treatment, Zepbound, other drugs

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound

The Independent UK

Eli Lilly Launches Unique Website Connecting Patients to Obesity Care+

Eli Lilly launches LillyDirect, a one-of-a-kind website connecting patients seeking obesity treatment to doctors and its weight-loss drug. Streamlining hea...

Top News

Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of diabetes and obesity

The news comes as rampant demand for the reputed “miracle drugs” leads to nationwide shortages.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Stock: Buy or Sell?

Eli Lilly's diversified portfolio and high demand for its weight-loss drugs have pushed it to the top of Wall Street's list of top pharma stocks for 2024. Is now the time to buy?

Barchart

Insulin Now Available for $35 a Month for Many Americans

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

Kiplinger

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

The Independent UK

Career advice from the CFOs of Dell, Eli Lilly, and Marriott—3 women who have each spent 20-plus years climbing the ladder at one company

As the CFO role continues to evolve, the leaders also explained the integral part of being an effective finance chief.

Fortune

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

Zepbound is expected to be available in the U.S. by the end of the year.

Fortune

FDA approves Zepbound, a new obesity drug that will take on Wegovy

Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.

WEKU

Novo Nordisk isn’t alone: Sales of Wegovy rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Prescribe to Profits With These 3 Pharma Stocks

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.

StockNews.com

3 Pharma Stocks Smart Money Is Following in September

With the rising prevalence of chronic diseases, the demand for pharmaceutical products is anticipated to rise. Therefore, investors could consider buying three fundamentally robust pharma stocks, Eli Lilly and Company (LLY), Zoetis (ZTS), and Taro Pharmaceutical Industries (TARO), which are gaining traction among institutional investors this month. Learn more….

Barchart

Chart of the Day: Eli Lilly (LLY) Edges to New Record High

The Barchart Chart of the Day belongs to Eli Lilly (LLY) . I found the stock by using Barchart.com to find the "Barchart New Highs" page, and then I clicked on pull-down to select stocks with new 52-week highs. I then viewed the stocks on the list with the FlipCharts...

The Independent UK

Soaring sales of diabetes drug Mounjaro, often used for weight loss, sends Eli Lilly to new heights

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

Tribune News Service

Lilly applies for Alzheimer’s drug’s US approval after trial success

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

The Independent UK

Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening

Fortune

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

The Guardian - UK

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

Tribune News Service

Lisa Jarvis: Eli Lilly’s new weight-loss drug is even better than Ozempic

New data from an experimental drug being developed by Eli Lilly & Co. raises an intriguing question about obesity treatments: How low can the weight loss go?

StockNews.com

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.